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Abstract: Renal cell carcinoma (RCC) is a relatively rare malignancy of the urinary tract system. RCC
is a heterogenous disease in terms of underlying histology and its associated underlying pathobiology,
prognosis and treatment schedule. The most prevalent histological RCC subtype is clear-cell renal
cell carcinoma (ccRCC), accounting for about 70–80% of all RCCs. Though the pathobiology and
treatment schedule for ccRCC are well-established, non-ccRCC subtypes account for 20%–30% of RCC
altogether, and their underlying molecular biology and treatment options are poorly defined. The class
of non-coding RNAs—molecules that are generally not translated into proteins—are new cancer
drivers and suppressors in all types of cancer. Of these, small non-coding microRNAs (miRNAs)
contribute to carcinogenesis by regulating posttranscriptional gene silencing. Additionally, a growing
body of evidence supports the role of long non-coding RNAs (lncRNAs) in cancer development and
progression. Most studies on non-coding RNAs in RCC focus on clear-cell histology, and there is a
relatively limited number of studies on non-ccRCC subtypes. The aim of this review is to give an
overview of the current knowledge regarding the role of non-coding RNAs (including short and long
non-coding RNAs) in non-ccRCC and to highlight possible implications as diagnostic, prognostic and
predictive biomarkers.
Keywords: renal cell carcinoma; non-clear cell; lncRNA; miRNA; long noncoding RNA;
microRNA biomarker
1. Introduction
Kidney cancer is the third most common malignancy of the genitourinary system in females
and the second most common in males [1]. In the USA, in 2019, an estimated 73,800 patients will be
newly diagnosed with, and 14,770 will die from, kidney cancer [1]. The incidence of kidney cancer
worldwide accounts for 2.4%, measuring up to 338,000 new cases and 144,000 deaths each year in
total [2]. The majority of kidney cancer is diagnosed as renal cell carcinoma (RCC), which accounts for
90% of all renal malignancies [3]. Although a stage migration toward earlier tumor stages occurred
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in the last two decades [4], cancers of the kidney are responsible for approximately 144,000 deaths
annually worldwide [2].
RCC is classified according to its underlying histology, which is defined by distinctive
morphological and histological criteria [5]. The most prevalent subtype of RCC is clear-cell renal
cell carcinoma (ccRCC), which accounts for 70–80% of all RCC cases. The second and third most
common subtypes are papillary (pRCC) and chromophobe (chRCC) renal cell carcinomas, representing
10–15% and 3–5% of RCC, respectively [6]. Other known, but very rare, subtypes include tubulocystic
(tcRCC) and clear-cell papillary renal cell carcinoma (ccpRCC) [5]. Several prognostic factors have been
identified within recent years including blood-based [7,8] and tissue-based parameters [9,10], which
have been summarized in different prognostic scores and prediction tools [11–13]. Unfortunately, up
to 30% of patients initially present with metastatic disease or develop metastasis within the first two
years after diagnosis [14]. Depending on the risk stratification criteria, in this setting, median survival
times are 43.2, 22.5 and 7.8 months for good, intermediate and poor risk groups, respectively [15].
Nonetheless, due to the recent introduction of checkpoint inhibitors in the first-line treatment of
intermediate or poor risk advanced or metastatic RCC, the prognosis has become more favorable [16].
Yet, this relates only to ccRCC, since the major studies leading to this revolution in RCC-treatment
included only patients with clear-cell morphology [17–20]. As a result, data from large randomized
clinical phase III trials on immunotherapy in non-ccRCC are widely missing.
One major reason for the lack of clinical trials in non-clear cell RCC is its heterogenous underlying
biology. This also conveys to the emerging field of non-coding RNA in cancer, where a high number
of studies reported on the impact of microRNAs (miRNAs) on cancer development, progression and
potential clinical implications in ccRCC. Data on miRNAs and long non-coding RNAs (lncRNAs) in
non-clear cell RCC remains limited. In general, miRNAs represent small RNA molecules composed
of about 19–25 nucleotides, which are not coding for proteins. They contribute to the regulation of
posttranscriptional gene silencing as they bind to the 3′-untranslated region (3′-UTR) of the targeted
messenger RNA of the respective target gene, thus leading to its degradation or destabilization and
consequently, inhibited translation [21] (Figure 1). This happens due to the miRNA’s association with
Argonaute (Ago) proteins. Together, they form the RNA-induced silencing complex (RISC) [21].
A single miRNA may target more than 100 possible different sites [22]. The impact of miRNAs
in cancer has been investigated in various cancer entities, such as colorectal cancer [23–25], testicular
cancer [26,27], B-cell lymphoma [28], breast cancer [29], glioma [30–32], nephroblastoma [33], pancreatic
cancer [34] or leukemia [35,36]. miRNAs were said to contribute to cancer development, progression
or even drug resistance, and may be used as future biomarkers or in cancer therapy [37,38].
In contrast to the shorter miRNAs, lncRNAs are defined as longer than 200 nucleotides in length
and are commonly located in the nucleus of a cell [39,40]. In recent years, different functions of
lncRNAs have been demonstrated (Figure 2). lncRNAs may act as a decoy for other molecules [41],
for instance, miRNAs, thus leading to less translational repression, degradation or destabilization of
the target mRNAs [42]. Further mechanisms include guide [43] and scaffold [44] lncRNAs and the
involvement in transcription regulation [39,42]. In cancer, lncRNAs were shown to influence gene
transcription, as well as cell cycle regulation and proliferation, thus representing potential therapeutic
targets [45,46].
The present review aims to summarize the current literature of non-coding RNA research in five
non-clear cell RCC histologies and to focus on their potential clinical implementations in diagnosis,
prognosis and therapy.
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Figure 1. Schematic representation of microRNAs (miRNA) biogenesis and mode of action.
Transcription of a miRNA gene is mostly conducted by RNA Polymerase II (pri-miRNA), followed by
processing via Drosha/DGCR8 complex into a precursor hairpin miRNA (pre-miRNA). After nuclear
export via Exportin 5/RanGTP, the pre-miRNA is processed by Dicer/TRBP into a miRNA duplex
without hairpin. One strand of the mature RNA duplex associates with the Argonaut/RISC complex
and guides the whole complex to the target mRNA (violet). Consequences of miRNA binding to the
mRNA target are translational repression, destabilization or degradation of the target mRNA.
Cancers 2019, 11, 1580 4 of 19
Figure 2. Graphical overview of cellular lncRNA actions. Decoy: long non-coding RNAs (lncRNA) can
act as molecular sponges for miRNAs and transcription factors (not depicted), thereby preventing these
molecules from binding to their actual targets. Transcription regulation: in combination with diverse
transcription factors, lncRNAs possess the ability to regulate cellular transcription. Guide: lncRNA can
act as guides for chromatin-modifying enzymes to target genes. Scaffold: lncRNAs are able to form
ribonucleoprotein complexes with different protein partners. This complex, consisting of lncRNAs and
proteins can regulate transcription. In each panel, representative examples of lncRNAs are given.
2. Methods
The literature research was conducted using the PUBMED database. Various combinations of the
search terms “renal cell carcinoma”, “kidney cancer”, “papillary”, “chromophobe”, “tubulocystic”,
“clear cell papillary”, “non-clear cell”, “long non coding RNA”, “lncRNA”, “microRNA”, “miRNA” or
“non-coding RNA” were used and article headlines, abstracts and full texts were screened for relevance
on the topic. Studies that investigated non-coding RNAs in at least one non-clear cell RCC subtype
were included in this review.
3. Discussion
3.1. Role of microRNAs in Non-Clear Cell RCC
3.1.1. Papillary Renal Cell Carcinoma
With a prevalence of about 10% of all RCC cases, pRCC is the second most common histological
subtype of RCC [47] and can be differentiated into two different subsets by distinctive histological
and molecular findings [48]. Both type 1 and type 2 are characterized by mostly papillary and
tubular structures. However, in type 1, these respective structures are predominantly covered by
small cells with pale cytoplasm and small oval nuclei, whereas in type 2, they are covered by larger
eosinophilic cells with large spherical nuclei [49]. A large proportion of type 1 tumors have multiple
chromosomal alterations, the most frequent of which are gains of chromosomes 7 and 17. In addition,
MET mutations are common in type 1 tumors. In type 2, CDKN2A alterations, either by mutations
or by hypermethylation, occur frequently [50]. Overall, patients with pRCC have a better survival
outcome than those with ccRCC; however, type 2 tumors are usually more aggressive and have a
greater metastatic potential [9]. Therefore, type 2 pRCC has a poorer prognosis than type 1 papillary
and even ccRCC [51,52].
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Diagnostic Potential of miRNAs in pRCC
The number of miRNAs with potential for diagnostic purposes is described in this paragraph.
miR-21 is upregulated in malignant renal tumors compared to healthy renal tissue [53,54] and is
linked to tumor growth, cancer progression and metastases [55]. Interestingly, different levels of
miR-21 expression have been found among different renal tumor subtypes. There is a significantly
higher expression of miR-21 in clear-cell and papillary subtypes, in contrast with chromophobe RCC
and oncocytoma [53,56]. In addition, in pRCC, increased miR-21 expression (gene locus 17q23.1) is
linked to copy number changes of the genome, since pRCC cells feature a high frequency of trisomy
17 and, therefore, an increase of the related gene products [56]. As mentioned earlier, numerical
chromosomal alterations are more frequently associated with type 1 pRCC [50]. Thus, miR-21 could
be used to distinguish between these respective RCC subtypes on a molecular basis with relatively
high sensitivity (83%) and specificity (90%); however, a differentiation of ccRCC and pRCC cannot
be achieved by using miR-21 only, meaning that molecular diagnostics are not a substitute for an
experienced pathologist [53].
On the other hand, Powers and colleagues [56] identified 3 miRNAs with distinctive levels of
expression in ccRCC and pRCC. miR-126, miR-126* and miR-143 were significantly upregulated in
ccRCC compared to pRCC, which made it possible to distinguish between the respective two RCC
subtypes [56].
The downregulation of miR-126 in pRCC relative to ccRCC was confirmed by another study
that also aimed to correctly discriminate between different RCC subtypes [57]. A two-step model for
differentiating ccRCC and pRCC from chRCC and oncocytoma was proposed by Di Meo et al. [57] based
on the expression rates of miR-221, miR-222 and miR-126. The first step takes into consideration the
differential expression rates of either miR-221 or miR-222. Both, miR-221 and miR-222 display decreased
expression levels in carcinomas with clear-cell or papillary morphology. The second step involves
discriminating between ccRCC and pRCC based on the expression rate of miR-126, which is increased
in ccRCC compared to pRCC [57]. The location of miR-126 on chromosome 9 (gene locus 9p34.3) and
the frequent loss of chromosome 9p characteristic for type 2 pRCC might be a feasible explanation for
the lower expression compared to ccRCC [50,57]. Regarding the role of miR-126 in carcinogenesis,
miR-126 targets the 3′-UTR of vascular endothelial growth factor A (VEGF-A) [58] and additionally,
expression levels correlate inversely with the expression of epidermal growth factor-like domain 7
(EGFL7) [59]. Both, VEGF-A and EGFL7 are involved in tumor angiogenesis [58,59]. Furthermore,
miR-126 may be involved in the regulation of the PI3K/Akt pathway [60].
Wach and colleagues [61] conceived a study in which, besides the discrimination of both healthy
and cancer tissue, as well as ccRCC and pRCC subtypes, they were also able to differentiate type 1
and 2 of pRCC by using a multistep combination of miRNAs. In the first step, the miRNAs used
to distinguish between healthy and tumor tissue were miR-145, miR-200c, miR-210 and mi-R502-3p.
In the second step, miR-145 and miR-503-3p were used to classify ccRCC versus pRCC, whereas in the
third step, type 1 and 2 were distinguished by utilizing miR-210 and miRNA let-7c. Both, miR-210
and let-7c were upregulated in type 1 pRCC as compared with type 2. The subtypes were classified
correctly in 86.5%, 77.6% and 86.4% for the first, second and third discrimination, respectively [61].
miR-210 is linked to hypoxia in cancer tissue and is directly involved in the hypoxia pathway.
Hypoxia-induced factor 1 alpha (HIF1α) binds to its promotor region, thus inducing the transcription
of miR-210 in a proposed positive feedback loop [62,63]. Nonetheless, higher HIF1α levels and,
consequently, elevated miR-210 expression may also occur in non-hypoxic states due to mutations of
the Von Hippel Lindau (VHL) gene, which leads to insufficient HIF1α-degradation [64]. To explain the
relatively low miR-210 expression in type 2 pRCC, Wach et al. suggest less dependence on hypoxia in
type 2 compared to type 1 pRCC [61]. Furthermore, miR-210 is upregulated in various other cancer
entities, including ccRCC [62,65], and has been introduced as a possible diagnostic and prognostic
biomarker in RCC, as well as for other malignancies, such as colorectal cancer [66,67].
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Targets of the let-7 family include the oncogenes RAS and MYC, making let-7 family members
veritable tumor-suppressing miRNAs. The relative downregulation of let-7c in type 2 pRCC
corroborates the recent discovery of MYC overexpression in the respective subtype [61,68]. In addition,
immunohistochemical MYC straining patterns could discriminate prognostic groups in type 1
pRCC [69].
Regarding the distinction of RCC subtypes, miR-155 showed higher expression levels in ccRCC
compared to pRCC and, therefore, could be useful in the distinction of the two subtypes [54]. Moreover,
miR-155 also carries prognostic information, as its overexpression is related to decreased disease-specific
survival (DSS) in RCC, although this only prevailed in the univariate analysis [54]. miR-155 is located
on chromosome 21 (gene locus 21q21.2–21.3) and is linked to tumor proliferation. It directly targets
nedd4-family interacting protein 1 (NDFIP1), which is a part of the regulation of PTEN (Phosphatase
and tensin homolog) [70], a commonly known apoptosis-promoting tumor suppressor gene in various
solid malignancies that is also associated with poorer survival in kidney cancer [71]. miR-155 may
target the 3′-UTR of PTEN mRNA directly as well, leading to an activation of the PI3K/Akt pathway and
thus, promoting tumor progression [72]. Other functions of miR-155 that are related to carcinogenesis
are targeting the tumor suppressor DMTF1 (Cyclin D Binding Myb-Like Transcription Factor 1) and
enhancing the Wnt/beta-catenin pathway [31,73].
Prognostic Potential of miRNAs in pRCC
miRNAs are not only useful as potential diagnostic biomarkers but have also proven to be
of prognostic significance in various cancer entities, such as breast, gastric, colon and prostate
cancer [74–77]. Other than the previously discussed studies, which mainly addressed the potential of
microRNAs in diagnosis and the classification of RCC, some studies also focused on their possible
prognostic value in pRCC (Table 1).
Table 1. miRNAs significantly associated with outcomes in non-ccRCC.
Reference miRNA ExpressionLevel Endpoint Outcome
Independent in
Multivariate Analysis
papillary RCC
Ge et al., 2015 [78]
miR-200c ↓ OS good no
miR-127 ↓ OS good no
miR-34a ↑ OS good yes
Luo et al., 2017 [79] hsa-miR-1293 ↑ PFS poor N/E
hsa-miR-3199-2 ↑ PFS poor N/E
Huang et al., 2017 [80]
miR-133a ↑ OS poor N/E
miR-133b ↑ OS poor N/E
miR-145 ↑ OS poor no
miR-216a ↑ OS poor N/E
miR-217 ↑ OS poor N/E
miR-1297 ↑ OS poor N/E
miR-211 ↑ OS good N/E
chromophobe RCC
Ge et al., 2015 [81]
miR-191 ↑ RFS, OS poor no
miR-19a ↑ RFS, OS poor no
miR-210 ↑ RFS, OS poor yes (RFS)
miR-425 ↑ RFS, OS poor no
miR-186 ↑ OS poor no
Abbreviations: RCC—renal cell carcinoma; OS—overall survival; PFS—progression-free survival;
RFS—recurrence-free survival; N/E—not evaluated, no multivariate analysis conducted.
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Decreased expression levels of miR-200c and miR-127, as well as high levels of miR-34a, were
associated with better overall survival (OS) in patients with pRCC [78]. However, only miR-34a
proved to be an independent prognostic marker in the multivariate analysis in the validation stage [78].
miR-200c was shown to be dysregulated in many solid tumor entities, such as, but not limited to,
bladder, breast, colorectal, gastric and lung cancer [82]. Moreover, it is involved in the proliferation
and differentiation of normal and cancer stem cells and, by modifying the cellular sensitivity to death
receptor CD95, in the regulation of apoptosis. miR-200c may also suppress endothelial-to-mesenchymal
transmission (EMT) and, therefore, inhibit tumor progression [82].
miR-34a may function as a tumor suppressor, which could illuminate why higher expression
levels favor a better prognosis. E2F3, MET and Fra-1 are associated targets of miR-34a [83–85].
Other miRNAs analyzed in respect of their prognostic potential are hsa-miR-1293 and hsa-miR-3199
2 [79]. In the study, the cut-off was chosen as the median expression level. A significant difference
in progression-free survival (PFS) in a 5-year follow-up for high-risk (39.4%) and low-risk (70.3%)
groups was reported [79]. However, the inclusion of both metastasized and non-metastasized patients
in the analysis must be noted as a limitation of the study regarding the calculation of PFS. Except
for hsa-miR-1193, which was also shown to relate to lung cancer [86], to date, there are no studies to
validate their involvement in carcinogenesis and tumor progression.
In a competing endogenous RNA (ceRNA) network analysis, seven miRNAs have been found
that may be promising candidates as prognostic biomarkers in pRCC [80]. Higher expression levels
of hsa-miR-133a, hsa-miR-133b, hsa-miR-145, hsa-miR-216a, hsa-miR-217 and hsa-miR-1297 were
associated with detrimental effects on OS. As opposed to this, an increased expression of hsa-miR-211
was connected to a better OS [80]. However, since no uni- and multivariate models were used in the
survival analysis, there is not enough evidence to support the prognostic impact of the respective
miRNAs, yet. As for miR-145, at least in the previously mentioned study of Wach et al. [61], it did not
independently predict prognosis, as it failed to reach statistical significance in multivariate models.
3.1.2. Chromophobe Renal Cell Carcinoma
chRCC is the third most common subtype of RCC and accounts for 5% of this cancer entity [47,87].
Metastatic disease at diagnosis is less common in patients with chRCC than with ccRCC and altogether,
chRCC has more favorable survival rates. However, this is not true for advanced metastatic chRCC,
which shows a less favorable outcome [88].
The diagnosis of chRCC by morphologic characteristics alone can be difficult, since the eosinophilic
variant of ccRCC, and especially oncocytoma, are possible differential diagnoses, which all show
oncocytic histological features [89].
Diagnostic Potential of miRNAs in chRCC
As shown previously, the use of miRNAs could facilitate the correct subtyping of RCC, including
chRCC. Multiple studies have already investigated the diagnostic potential of miRNAs in chRCC,
focusing especially on the discrimination of chRCC and oncocytoma [56,57,90–92].
miR-221 and miR-222 are consistently overexpressed in both chRCC and
oncocytoma [56,57,90,91,93]. Altered expression patterns have already been demonstrated in
multiple other solid malignancies, including glioma, colorectal, gastric, breast and prostate
cancer [32,94–97]. In ccRCC, targeting TIMP2 (Tissue inhibitor of metalloproteinases 2), miR-221 was
reported to enhance proliferation, migration and invasion [98]. Moreover, high expressions of both,
miR-221 and miR-222 are associated with poorer treatment response in patients with metastatic renal
cell carcinoma treated with the multikinase inhibitor sunitinib. Potential targets of miR-221/222 are
VEGFR2 and c-KIT, which are both targets of sunitinib [99].
miR-203 is upregulated in chRCC relative to oncocytoma [90]. Conversely, it is downregulated in
ccRCC, which was associated with worse outcome. Also, transient forced expression resulted in the
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inhibition of further proliferation and metastatic spread, which indicates the tumor suppressing role of
miR-203 in renal neoplasms. miR-203 directly targets fibroblast growth factor 2 (FGF2) [100].
Powers et al. [56] found miR-429, miR-200b, miR-629* and miR-124 to be significantly differentially
expressed between chRCC and oncocytoma and relatively overexpressed in chRCC, respectively. In
addition, miR-200c was increased in chRCC.
miR-200b/c and miR-429 are members of the miR-200 family, which targets the EMT-activating
transcription factors ZEB1 and ZEB2. As a result, the miR-200 family is connected to the regulation of
EMT [101]. EMT, a hallmark of cancer, is an important step in the disease progression, as it comes with
increased invasive and metastatic potential of cancer cells [102].
The distinctive miRNA characteristics of chRCC were used in a tested two-step model for the
differentiation of RCC subtypes. miR-221 and miR-222 could correctly distinguish ccRCC and pRCC
from chRCC and oncocytoma, respectively, since they show inverse levels of expression. In a second
step, regarding the subclassification of tumors, miR-200b, miR-200c and miR-222 could significantly
distinguish chRCC form oncocytoma. Interestingly, miR-200b alone showed greater discriminatory
ability than various combinations among these miRNAs and could differentiate chRCC and oncocytoma
with a sensitivity and specificity of over 89% and 90%, respectively [57].
Another study of Fridman et al. [92] also used a two-step approach to identify RCC subtypes
and oncocytomas. Expression levels of miR-221 and miR-210 differentiated the pairs of chRCC and
oncocytoma versus ccRCC and pRCC, whereas miR-200c and miR-139-5p were used to identify chRCC
or oncocytoma.
Prognostic Potential of miRNAs in chRCC
Pretreatment expression levels of specific miRNAs may also qualify as prognostic biomarkers in
chRCC. miR-191, miR-19a, miR-210 and miR-425 were associated with recurrence-free survival (RFS)
in a retrospective study including 58 patients with primary chRCC. However, only miR-210 proved
to be an independent biomarker for RFS in the uni- and multivariate Cox analysis. Moreover, high
expression of the respective miRNAs and additionally, of miR-186 was associated with shorter OS, yet
this did not prevail in the uni- and multivariate analysis. Notably, the relatively short median follow-up
of 63 months, at a 5-year survival of 85% in chRCC may contribute to the insignificant results [81].
Nonetheless, the results of this study are in line with previous studies, which found overexpression of
miR-210 in adverse prognosis of ccRCC [103].
3.1.3. Tubulocystic Renal Cell Carcinoma
tcRCC is an extremely rare histological subtype of RCC, that is often an incidental finding
of radiological evaluation of Bosniak type III and IV cysts of the kidney [104]. As the tumor is
indolent in most cases, patients usually present themselves asymptomatic at diagnosis and rarely
metastasized [105]. Macroscopically, it features multiple cysts varying in size. Histologically, it
shows enlarged nucleoli and an eosinophilic cytoplasm similar to oncocytomas [5]. Therefore, the
differentiation of tcRCC from other RCC subtypes and oncocytomas may be difficult [106]. However,
molecular profiling, as well as a unique miRNA expression profile may facilitate diagnosis of tcRCC.
miRNA Expression in tcRCC
One study focused on tcRCC and compared miRNA expression levels with other RCC subtypes,
namely ccRCC, pRCC and ccpRCC [107]. miR-138, miR-200c and miR-182 were found to be upregulated
in tcRCC compared to the other subtypes; however, the difference for miR-182 was not significant [107].
Additionally, downregulated expressions of miR-210, miR-34a and miR-155 were noted; however,
only the expression levels of miR-155 were significantly decreased compared to both ccRCC and
pRCC, whereas miR-210 and miR-34a were significantly downregulated compared to both ccRCC
or pRCC [107]. The roles of miR-155 and miR-210 in cancer have already been discussed. As for
miR-34a, it is closely related to p53, an important and commonly known tumor suppressor, which
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is frequently mutated across multiple cancer entities. It transcriptionally controls the expression of
miR-34a [108]. miR-34a itself is seen as a tumor suppressor, as its targets are widely associated with
proliferation processes, apoptosis, cell aging, cancer stem-like cell phenotype, EMT, cell motility and
even immune evasion [108]. Furthermore, miR-34a is upregulated in ccRCC [109]. Amongst others,
promising targets are MYC, NOTCH1, MET, BCL2, CD44 or PD-L1 [108]. As a result, a phase I trial
testing a liposomal miR-34a mimic has been conducted, for possible implementation in the future
treatment of cancer [110].
In the study by Lawrie et al. [107], no alteration of miRNA expression was distinctive for tcRCC
only. Nonetheless, a combination of different miRNAs may be used to discriminate tcRCC from other
RCC subtypes in future studies.
3.1.4. Clear-cell Papillary Renal Cell Carcinoma
ccpRCC is a rare, mostly indolent subtype of renal cancer that accounts for up to 5% of resected
renal tumors [111]. Higher incidence is seen in patients with end-stage renal disease or chronic
kidney disease [112]. Histologically, it shows low-grade clear epithelial cells in a tubular and papillary
arrangement [5].
miRNA Expression in ccpRCC
miR-200a, miR-200b, miR-200c, miR-141 and miR-429, which are all part of the miR-200 family,
are consistently upregulated in ccpRCC. However, they are downregulated in other renal carcinoma
subtypes, including clear-cell and papillary morphology subsets [113,114].
As the miR-200 family is linked to the regulation of EMT [115], Lawrie et al. [113] further
show that, conversely to renal neoplasms with clear-cell morphology in ccpRCC, the markers
vimentin (mesenchymal), E-cadherin (epithelial) and β-catenin (mesenchymal) were all positive
in immunofluorescent staining. Due to this unique characteristic, indicating incomplete EMT in
ccpRCC, the authors suggest a potential use in differential diagnosis of RCC subtypes [113].
Furthermore, ccpRCC shows high levels of miR-210 expression [113,114]. As previously stated,
miR-210 is involved in the hypoxia pathway [62,113,114], which activation has already been shown in
ccpRCC. However, this activation is independent of the usual hypoxia pathway-linked functional loss of
the Von Hippel Lindau (VHL) gene, which is still functional in ccpRCC as opposed to ccRCC [114,116].
Respectively, Lawrie et al. [113] suggest epigenetic regulation as a possible explanation, as they found
two specific miRNAs (miR-885 and miR-378b), located downstream and close to the VHL gene, being
upregulated in ccpRCC. Additional miRNAs found to be overexpressed in ccpRCC are miR-34a,
miR-182, miR-424, miR-122, miR-21, miR-34b*, miR-489 [113,114]. miR-122 might be connected to
the regulation of VHL and, therefore, also be involved in the hypoxia pathway [117]. In addition, it
contributes to proliferation, invasion and an increased metastatic potential in ccRCC [118–120].
Downregulated miRNAs in ccpRCC are miR-4284, miR-1202, miR-135a, miR-1973 and
miR-204 [114]. Interestingly, patterns of upregulated miRNAs expression are highly similar in
ccpRCC and ccRCC, whereas the same applies for ccpRCC and pRCC in terms of downregulated
miRNA expression [114].
3.1.5. Xp11 Translocation Renal Cell Carcinoma
Xp11 translocation RCC is the most common renal neoplasm in children. However, it is also seen
in adults, where its prevalence may be underestimated. Xp11 RCCs show characteristic chromosomal
translocations at a breaking point—the locus Xp11.2—resulting in a distinctive gene fusion including
the TFE3 transcription factor gene. Microscopically, this results in a tumor showing clear cells, as well
as papillary structures [121].
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miRNA Expression in Xp11 RCC
In a genome-wide miRNA expression profile analysis, the expression levels of several miRNAs
were found to be specifically altered in Xp11 RCC relative to other malignancies of the kidney,
such as ccRCC, pRCC and ccpRCC. Compared to healthy renal tissue, miR-148a-3p, miR-221 3p,
miR-185-5p, miR 196b-5p and miR-642a-5p are upregulated, whereas miR-133b and miR-658 were
downregulated [122].
Regarding the overall miRNA expression profiles, they were most similar to ccpRCC and showed
the biggest difference to pRCC, respectively [122].
3.2. Role of lncRNAs in Non-Clear Cell RCC
3.2.1. Papillary Renal Cell Carcinoma
Mutations of the putative promoter region of the lncRNA NEAT1 (nuclear-enriched abundant
transcript 1) were found in 17% of pRCC. This came along with an overexpression of NEAT1 and
is associated with decreased survival. Additionally, lncRNA MALAT1 (metastasis-associated lung
adenocarcinoma transcript 1) was co-expressed with NEAT1 in pRCC, as well as in ccRCC [123].
NEAT1 is frequently overexpressed in cancer tissues, including ccRCC, where it is linked to EMT and
chemoresistance by competing with miR-34a and thus, influencing the miR-34a/c Met axis [124,125].
Mounting evidence suggests the role of NEAT1 as a competitive endogenous RNA and proposes its
potential use as a biomarker and therapeutic target in cancer [124]. MALAT1 was shown to influence
tumor progression and prognosis in ccRCC, as well as acting as a competing endogenous RNA by
sponging the miRNA-200 family [126,127] (Figure 2).
In a ceRNA network analysis using the TCGA (The Cancer Genome Atlas) database, lncRNA
PVT1 (Plasmacytoma Variant Translocation 1) was suggested to compete with three miRNAs,
namely miR-133a, miR-133b and miR-145, thus regulating the expression of the SP1 gene. SP1
is a transcription factor involved in many tumorigenesis-associated processes and was identified as a
potential target of the respective miRNAs. In the study, an increased expression of PVT1 was associated
with shorter OS. Furthermore, high levels of lncRNAs AC003092.1, RP6-191P20.4, RP11-401P9.4
and RP11-496D24.2 correlated with worse prognosis [80]. However, these results should only be
viewed as hypothesis-generating, since uni- and multivariate regression models were not used in the
survival analysis.
Luo et al. [128], too, conducted a ceRNA network analysis using the TCGA database and found
lncRNA MEG3 (maternally expressed 3) to be significantly downregulated in pRCC compared to
healthy kidney tissue. MEG3 was suggested to be an important regulator in the network, as it was
shown to potentially interact with 14 differentially expressed miRNAs in pRCC, more than any other
lncRNA in the study [128]. The role of MEG3 as a tumor suppressor was shown in various cancers
such as pancreatic, breast, esophageal and gastric cancer [129–132]. In ccRCC, MEG3 expression was
shown to be downregulated, resulting in decreased apoptosis and accelerated proliferation, migration
and invasion, due to its regulatory influence on miR-7/RASL11B signaling [133]. Furthermore, in the
present study on pRCC, MEG3 was identified as part of a subnetwork together with lncRNA PWRN1
(Prader-Willi Region Non-Protein Coding RNA 1), miR-508 and miR-21 [128].
lncRNAs may be promising prognostic biomarkers in pRCC (Table 2).
Lan and colleagues [134] created a prognostic index including seven differentially expressed
lncRNAs that each independently predicted for cumulative survival. High expression of lncRNA
AFAP1-AS1, as well as low expressions of lncRNAs GAS6-AS1, RP11-1C8.7, RP11-21L19.1,
RP11-503C24.1, RP11536I6.2 and RP11-63A11.1, were significantly associated with worse prognosis.
The calculated prognostic index combining the prognostic value of these lncRNAs could independently
differentiate between high- and low-risk groups with an average survival of 109.4 vs. 117.3 months,
respectively. The prognostic index also predicted for clinicopathological stages, such as metastasis,
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nodal invasion and tumor stages [134]. However, the analysis was carried out within the TCGA
database and needs further experiments and verification.
Another approach to combine the prognostic value of individual differentially expressed lncRNAs
in three subtypes of RCC was suggested by Zuo and colleagues [135]. A prognostic signature of six
lncRNAs, independently predicting for OS in all three, ccRCC, pRCC and chRCC, respectively, was
established. The lncRNAs included in the signature are AC003092.1, AC079160.1, COL18A1-AS1,
LINC00520, LINC02154 and SLC7A11-AS1. All lncRNAs were upregulated in the tumor tissue,
compared to healthy renal tissue, and upregulated in high-risk vs low-risk groups, except for
COL18A1-AS1, which showed converse behavior. The six lncRNA signatures could also distinguish
good and poor prognostic groups within independent prognostic factors such as age, stage III and
stage IV [135]. This study, too, was conducted using the TCGA database.
Table 2. lncRNAs significantly associated with outcomes in non-ccRCC.
Reference lncRNA ExpressionLevel Endpoint Outcome
Independent in
Multivariate Analysis
PapillaryRCC
Lan et al., 2017 [134]
AFAP1-AS1 ↑ OS poor N/E *
GAS6-AS1 ↓ OS poor N/E *
RP11-1C8.7 ↓ OS poor N/E *
RP11-21L19.1 ↓ OS poor N/E *
RP11-503C24.1 ↓ OS poor N/E *
RP11536I6.2 ↓ OS poor N/E *
RP11-63A11.1 ↓ OS poor N/E *
Zuo et al., 2018 [135]
AC003092.1 ↑ OS poor N/E *
AC079160.1 ↑ OS poor N/E *
COL18A1-AS1 ↓ OS poor N/E *
LINC00520 ↑ OS poor N/E *
LINC02154 ↑ OS poor N/E *
SLC7A11-AS1 ↑ OS poor N/E *
chromophobe RCC
He et al., 2016 [136]
COL18A1-AS1 ↓ OS Poor N/E
BRE-AS1 ↓ OS Poor N/E
SNHG7 ↓ OS Poor N/E
TMEM51-AS1 ↓ OS Poor N/E
C21orf62-AS1 ↓ OS Poor N/E
LINC00336 ↓ OS Poor N/E
LINC00882 ↑ OS poor N/E
Abbreviations: RCC—renal cell carcinoma; OS—overall survival; N/E—not evaluated; no multivariate analysis
conducted. * Combined prognostic indices proved as independent biomarkers.
3.2.2. Chromophobe Renal Cell Carcinoma
Data on lncRNA in chRCC is limited. Seven lncRNAs were reported to be associated with
prognosis and, therefore, may be used as future biomarkers in chRCC. He et al. [136] performed a
ceRNA network analysis and described 16 lncRNAs and 18 miRNAs that might interact with each
other, influencing 12 cancer-related pathways.
Moreover, low levels of the six lncRNAs COL18A1-AS1, BRE-AS1, SNHG7, TMEM51-AS1,
C21orf62-AS1 and LINC00336 and high expression of LINC00882 significantly predicted for shorter
OS [136]. However, multivariate regression models were not used in the analysis. Additionally, the
patient cohort extracted from the TCGA database must be noted as a limitation and the results warrant
verification in other cohorts and by biological models [136].
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4. Conclusions
Important differences in miRNA expression patterns among non-clear cell RCC subtypes have been
demonstrated. Also, their potential use in diagnostics and differential diagnosis has been suggested;
however, further research is warranted to find the most suitable miRNAs for future implementation in
clinical practice. Moreover, besides their potential diagnostic capabilities, miRNA expression levels
convey prognostic and even predictive information in some non-clear cell RCC subtypes and may
influence clinical decision making.
As for lncRNA, data on non-ccRCC is limited and only available for two distinctive subtypes.
In papillary and chromophobe RCC, lncRNAs may represent novel prognostic biomarkers and add
further insight into the pathogenesis of RCC.
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